...
首页> 外文期刊>Open Heart >Original research article: Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers
【24h】

Original research article: Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers

机译:原始研究文章:坚持冠状动脉疾病二级预防药物:探索可改变的障碍

获取原文

摘要

Background Non-adherence to secondary prevention medicines (SPMs) among patients with coronary artery disease (CAD) remains a challenge in clinical practice. This study attempted to identify actual and potential modifiable barriers to adherence that can be addressed in cardiology clinical practice.Methods This was a cross-sectional, postal survey-based study of the medicines-taking experience of patients with CAD treated at a secondary/tertiary care centre. All participants had been on SPM for ≥3 months.Results In total, 696 eligible patients were sent the survey and 503 responded (72.3%). The median age was 70 years, and 403 (80.1%) were male; the median number of individual daily doses of all medicines was 6. The rate of non-adherence to at least one SPM was 43.5% (n=219), but 53.3% of reported non-adherence was to only one SPM. Statins contributed to 66.7% and aspirin to 61.7% of overall non-adherence identified by the Single Question (SQ) tool. In 30.8% of non-adherent patients (n=65), this was at least partly intentional. Barriers included forgetfulness (84.9%; n=186), worry that medicines will do more harm than good (33.8%; n=74), feeling hassled about medicines taking (18.7%; n=41), feeling worse when taking medicines (14.2%; n=31) and not being convinced of the benefit of medicines (9.1%; n=20). In a multivariate analysis, modifiable factors associated with overall non-adherence included being prescribed aspirin (OR: 2.22; 95% CI: 1.18 to 4.17), having specific concern about SPM (OR: 1.12; 95% CI: 1.07 to 1.18) and issues with repeat prescriptions (OR: 2.48; 95% CI: 1.26 to 4.90). Different factors were often associated with intentional versus unintentional non-adherence.Conclusions Using appropriate self-report tools, patients share actual and potential modifiable barriers to adherence that can be addressed in clinical practice. Non-adherence behaviour was selective. Most non-adherence was driven by forgetfulness, concern about the harm caused by SPM and practical barriers.
机译:背景技术在冠心病(CAD)患者中不遵守二级预防药物(SPM)仍然是临床实践中的挑战。这项研究试图确定可以在心脏病临床实践中解决的依从性的实际和潜在可改变障碍。方法这是一项基于邮政调查的横断面研究,研究了在二级/三级接受治疗的CAD患者的用药经验护理中心。所有参与者均接受了SPM≥3个月。结果总共对696名合格患者进行了调查,其中503名得到了回应(72.3%)。中位年龄为70岁,其中403人(占80.1%)为男性;所有药物的每日平均剂量中位数为6。不遵守至少一种SPM的比率为43.5%(n = 219),但是报告的不遵守一项仅5种SPM的比率为53.3%。单问(SQ)工具确定的他汀类药物占总体非依从性的66.7%,阿司匹林占61.7%。在30.8%的非依从性患者中(n = 65),这至少部分是故意的。障碍包括健忘(84.9%; n = 186),担心药物的弊大于利(33.8%; n = 74),服用药物时感到烦恼(18.7%; n = 41),服用药物时感觉更糟( 14.2%; n = 31),并且不相信药物的益处(9.1%; n = 20)。在多变量分析中,与总体不依从性相关的可改变因素包括处方阿司匹林(OR:2.22; 95%CI:1.18至4.17),特别关注SPM(OR:1.12; 95%CI:1.07至1.18)和重复处方的问题(OR:2.48; 95%CI:1.26至4.90)。结论故意与非故意的非依从性常常存在不同的因素。结论使用适当的自我报告工具,患者在遵守临床实践中可以解决实际和潜在的依从性障碍。不遵守行为是选择性的。大多数不遵守是由健忘,对SPM造成的危害以及实际障碍的担忧所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号